DCE-MRI in Patients with MRCC: Pilot Study Investigating Possible Biomarkers of Antiangiogenic Therapy

Andrew B. Gill¹, Gayathri D S Anandappa², Andrew N. Priest¹, Andrew J. Patterson¹, Martin J. Graves¹, Ilse Joubert¹, Louise M. Cookson³, Kate M. Fife², Philip S. Murphy³, Duncan B. Richards³, Evis Sala¹, Tim Eisen², Duncan I. Jodrell², David J. Lomas¹

This study investigated DCE-MRI indices as early indicators of the activity of the antiangiogenic drug bevacizumab when used in patients with metastatic renal cell carcinoma. Two base-line and two post-treatment examinations were performed on six patients. DCE-MRI data was analysed using an extended Tofts kinetic model with a model AIF to produce parameter maps which were then analysed to yield tumour medians. Significant reductions, compared to the mean of the base-line levels, were found in K^trans and v_p in tumours 3 days after treatment. IAUGC90 values showed a significant decrease both 4 hours after treatment and 3 days after treatment.